Found: 75
Select item for more details and to access through your institution.
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.
- Published in:
- EP: Europace, 2013, v. 15, n. 11, p. 1540, doi. 10.1093/europace/eut232
- By:
- Publication type:
- Article
Elevation of the glycoxidation product N<sup> ε</sup>-(carboxymethyl)lysine in patients presenting with acute myocardial infarction.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2009, v. 47, n. 4, p. 446, doi. 10.1515/CCLM.2009.100
- By:
- Publication type:
- Article
Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2008, v. 46, n. 2, p. 204, doi. 10.1515/CCLM.2008.040
- By:
- Publication type:
- Article
High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2007, v. 45, n. 10, p. 1360, doi. 10.1515/CCLM.2007.286
- By:
- Publication type:
- Article
Decreased plasmalogen concentration as a surrogate marker of oxidative stress in patients presenting with acute coronary syndromes or supraventricular tachycardias.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2007, v. 45, n. 5, p. 689, doi. 10.1515/CCLM.2007.111
- By:
- Publication type:
- Article
Time course of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2004, v. 42, n. 10, p. 1132, doi. 10.1515/CCLM.2004.232
- By:
- Publication type:
- Article
N-terminal pro-atrial natriuretic peptide as a biochemical marker of long-term interventional success after radiofrequency catheter ablation of paroxysmal supraventricular tachyarrhythmias[1)].
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2004, v. 42, n. 8, p. 896, doi. 10.1515/CCLM.2004.145
- By:
- Publication type:
- Article
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2578, doi. 10.1111/dom.15572
- By:
- Publication type:
- Article
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2775, doi. 10.1111/dom.14535
- By:
- Publication type:
- Article
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1141, doi. 10.1111/dom.14015
- By:
- Publication type:
- Article
Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria.
- Published in:
- PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0099276
- By:
- Publication type:
- Article
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 5, p. 396, doi. 10.1093/eurheartj/ehac693
- By:
- Publication type:
- Article
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 1, p. 41, doi. 10.1093/eurheartj/ehac530
- By:
- Publication type:
- Article
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
- Published in:
- European Heart Journal, 2022, v. 43, n. 36, p. 3435, doi. 10.1093/eurheartj/ehac320
- By:
- Publication type:
- Article
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
- Published in:
- European Heart Journal, 2022, v. 43, n. 5, p. 416, doi. 10.1093/eurheartj/ehab798
- By:
- Publication type:
- Article
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
- Published in:
- European Heart Journal, 2021, v. 42, n. 43, p. 4455, doi. 10.1093/eurheartj/ehab579
- By:
- Publication type:
- Article
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
- Published in:
- European Heart Journal, 2021, v. 42, n. 43, p. 4442, doi. 10.1093/eurheartj/ehab360
- By:
- Publication type:
- Article
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
- Published in:
- European Heart Journal, 2021, v. 42, n. 13, p. 1203, doi. 10.1093/eurheartj/ehaa1007
- By:
- Publication type:
- Article
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
- Published in:
- European Heart Journal, 2021, v. 42, n. 6, p. 671, doi. 10.1093/eurheartj/ehaa968
- By:
- Publication type:
- Article
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
- Published in:
- European Heart Journal, 2021, v. 42, n. 6, p. 700, doi. 10.1093/eurheartj/ehaa943
- By:
- Publication type:
- Article
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.
- Published in:
- European Heart Journal, 2020, v. 41, n. 30, p. 2848, doi. 10.1093/eurheartj/ehaa247
- By:
- Publication type:
- Article
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
- Published in:
- European Heart Journal, 2019, v. 40, n. 19, p. 1553, doi. 10.1093/eurheartj/ehz059
- By:
- Publication type:
- Article
Dabigatran etexilate for thromboprophylaxis ! in over 5000 hip or knee replacement patients in a real-world clinical setting.
- Published in:
- Thrombosis Journal, 2016, v. 14, p. 1, doi. 10.1186/s12959-016-0082-4
- By:
- Publication type:
- Article
Alterations of leptin in the course of inflammation and severe sepsis.
- Published in:
- BMC Infectious Diseases, 2012, v. 12, n. 1, p. 217, doi. 10.1186/1471-2334-12-217
- By:
- Publication type:
- Article
Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I.
- Published in:
- BMC Cardiovascular Disorders, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12872-015-0026-0
- By:
- Publication type:
- Article
Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Markers of Myocardial Damage, Tissue Healing, and Inflammation After Radiofrequency Catheter Ablation of Atrial Tachyarrhythmias.
- Published in:
- Journal of Cardiovascular Electrophysiology, 2004, v. 15, n. 6, p. 686, doi. 10.1046/j.1540-8167.2004.03371.x
- By:
- Publication type:
- Article
Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 9, p. 2215, doi. 10.1111/bcp.16099
- By:
- Publication type:
- Article
Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.
- Published in:
- Critical Care, 2014, v. 18, n. 5, p. 1, doi. 10.1186/s13054-014-0507-z
- By:
- Publication type:
- Article
Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Statin therapy of calcific aortic stenosis: hype or hope?
- Published in:
- European Heart Journal, 2006, v. 27, n. 7, p. 773, doi. 10.1093/eurheartj/ehi697
- By:
- Publication type:
- Article
Time-Dependent Changes in the Plasma Concentration of Matrix Metalloproteinase 9 after Acute Myocardial Infarction.
- Published in:
- Cardiology, 2003, v. 99, n. 3, p. 140, doi. 10.1159/000070670
- By:
- Publication type:
- Article
Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 900, doi. 10.1002/ejhf.3221
- By:
- Publication type:
- Article
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 963, doi. 10.1002/ejhf.3218
- By:
- Publication type:
- Article
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Preserved.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 885, doi. 10.1002/ejhf.3136
- By:
- Publication type:
- Article
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 10, p. 1797, doi. 10.1002/ejhf.2982
- By:
- Publication type:
- Article
Health status across major subgroups of patients with heart failure and preserved ejection fraction.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 9, p. 1623, doi. 10.1002/ejhf.2831
- By:
- Publication type:
- Article
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR‐Preserved trial.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 8, p. 1375, doi. 10.1002/ejhf.2922
- By:
- Publication type:
- Article
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 7, p. 970, doi. 10.1002/ejhf.2861
- By:
- Publication type:
- Article
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 12, p. 2297, doi. 10.1002/ejhf.2707
- By:
- Publication type:
- Article
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 10, p. 1844, doi. 10.1002/ejhf.2681
- By:
- Publication type:
- Article
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 10, p. 1883, doi. 10.1002/ejhf.2677
- By:
- Publication type:
- Article
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 8, p. 1400, doi. 10.1002/ejhf.2558
- By:
- Publication type:
- Article
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 10, p. 1798, doi. 10.1002/ejhf.2334
- By:
- Publication type:
- Article
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 9, p. 1529, doi. 10.1002/ejhf.2256
- By:
- Publication type:
- Article